RECRUITINGOBSERVATIONAL

Sepsis and Hospital Mortality

Sepsis Mortality in Hospitals: a Quality Indicator in Acute Care Settings

About This Trial

Sepsis is one of the leading causes of hospital mortality, with a rate of approximately 20% (World Health Organization) among vulnerable patients admitted to high-intensity care units such as CCUs and inpatient wards. Currently, diagnostic criteria such as the Systemic Inflammatory Response Syndrome (SIRS) and the Sequential Organ Failure Assessment (SOFA) score, although widely used, lack sufficient specificity and accuracy. No established parameters are available for early and timely diagnosis. This study aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes previously validated for non-invasive glucose monitoring. The acquired data will be analyzed using the Anritsu VectorStar VNA to identify innovative and reliable parameters associated with the presence of severe infections.

Who May Be Eligible (Plain English)

Who May Qualify: - Age ≥ 18 years - Cardiology patients without documented infection (Control Group) - Patients with sepsis - Patients with nosocomial infection - Patients with myocarditis, endocarditis, or pericarditis - Ability to provide written willing to sign a consent form Who Should NOT Join This Trial: - Patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune conditions (where your immune system attacks your own body)s, renal or hepatic failure - Patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants - Patients with cancer - Patients with diseases involving the immune system (e.g., lymphomas, leukemias) - Patients with congenital or acquired immunodeficiencies (e.g., HIV) - Patients who are unable to read and sign the willing to sign a consent form form Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Age ≥ 18 years * Cardiology patients without documented infection (Control Group) * Patients with sepsis * Patients with nosocomial infection * Patients with myocarditis, endocarditis, or pericarditis * Ability to provide written informed consent Exclusion Criteria: * Patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune diseases, renal or hepatic failure * Patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants * Patients with cancer * Patients with diseases involving the immune system (e.g., lymphomas, leukemias) * Patients with congenital or acquired immunodeficiencies (e.g., HIV) * Patients who are unable to read and sign the informed consent form

Treatments Being Tested

DIAGNOSTIC_TEST

conductivity and dieletric constant

collecting blood samples and directly measuring plasma conductivity and dielectric constant using microwave probes already validated for non-invasive glucose monitoring.

Locations (1)

''Annunziata'' Hospital

Cosenza, Italy